Castellani et al. noted that, in comparison to class I–III CFTR mutations, class IV and V mutations tend to be phenotypically dominant when occurring in combination with class I–III mutations, and those patients, presenting pancreatic insufficiency, have milder lung disease and live longer [9]. The gene discussed is CFTR; the disease is exocrine pancreatic insufficiency.